agreement-istock-480052842_mediaphotos
mediaphotos / iStockphoto.com
15 March 2017Americas

Mylan settles cancer drug patent dispute with Genentech

Mylan has entered a settlement with Genentech and its parent company, Roche, in relation to patents for cancer drug Herceptin (trastuzumab).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
12 April 2018   Japan-based Chugai Pharmaceuticals has announced it has withdrawn its patent infringement claim against generic anti-cancer business Nippon Kayaku.
Big Pharma
17 September 2020   The European Patent Office has invalidated and revoked a patent related to Teva’s multiple sclerosis drug Copaxone, in a win for Mylan.

More on this story

Asia
12 April 2018   Japan-based Chugai Pharmaceuticals has announced it has withdrawn its patent infringement claim against generic anti-cancer business Nippon Kayaku.
Big Pharma
17 September 2020   The European Patent Office has invalidated and revoked a patent related to Teva’s multiple sclerosis drug Copaxone, in a win for Mylan.

More on this story

Asia
12 April 2018   Japan-based Chugai Pharmaceuticals has announced it has withdrawn its patent infringement claim against generic anti-cancer business Nippon Kayaku.
Big Pharma
17 September 2020   The European Patent Office has invalidated and revoked a patent related to Teva’s multiple sclerosis drug Copaxone, in a win for Mylan.